Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.78 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.78 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.78 |
| ▸ | TNKS | O95271 | 1/20 | 0.78 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.78 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.78 |
| ▸ | PARP1 | P09874 | 2/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.53 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.53 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.53 |
| ▸ | GCK | P35557 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 3/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631040 | 0.88 | PARP10 (1.00) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL13687397 | 0.87 | PARP10 (0.78) | PARP10PARP14PARP15TNKSTNKS2 | |
| Methyl Alcohol SCHEMBL8784315 | 0.86 | PARP10 (0.77) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL2531295 | 0.86 | PARP10 (0.83) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL30434552 | 0.86 | PARP10 (0.83) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL2867826 | 0.85 | AKR1C3 (0.77) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL25910311 | 0.85 | MAOB (0.63) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL618677 | 0.85 | PARP10 (0.81) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL8736479 | 0.85 | MAOB (0.63) | PARP10PARP14PARP15TNKSTNKS2 | |
| Hydrochloric Acid SCHEMBL28772951 | 0.84 | PARP10 (0.80) | PARP10PARP14PARP15TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2007053574-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | PARP10 2976/4885PARP14 3437/4885PARP15 2744/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | PARP10 1667/4885PARP14 2378/4885PARP15 1591/4885 |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | MAPK1, MAPK8, MAPK3 | PARP10 3823/4885PARP14 4401/4885PARP15 3961/4885 |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | KIT, CHUK, IKBKB | PARP10 4490/4885PARP14 4456/4885PARP15 3769/4885 |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | PARP10 2343/4885PARP14 2123/4885PARP15 2799/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | PARP10 2954/4885PARP14 3129/4885PARP15 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.